Problems and emerging approaches in HIV/AIDS vaccine development

Fausto Titti, Aurelio Cafaro, Flavia Ferrantelli, Antonella Tripiciano, Sonia Moretti, Antonella Caputo, Riccardo Gavioli, Fabrizio Ensoli, Marjorie Robert-Guroff, Susan Barnett, Barbara Ensoli

Research output: Contribution to journalArticle

Abstract

According to recent estimates, 39.5 million people have been infected with HIV and 2.9 million have already died. The effect of HIV infection on individuals and communities is socially and economically devastating. Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, it has had a negligible impact on the global epidemic. Therefore, the need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of a vaccine against HIV/AIDS has turned out to be extremely challenging, as indicated by > 20 years of unsuccessful attempts. This review discusses the major challenges in the field and key experimental evidence providing a rationale for the use of non-structural HIV proteins, such as Rev, Tat and Nef, either in the native form or expressed by viral vectors such as a replicating adeno-vector. These non-structural proteins alone or in combination with modified structural HIV-1 Env proteins represent a novel strategy for both preventative and therapeutic HIV/AIDS vaccine development.

Original languageEnglish
Pages (from-to)23-48
Number of pages26
JournalExpert Opinion on Emerging Drugs
Volume12
Issue number1
DOIs
Publication statusPublished - Mar 2007

Fingerprint

AIDS Vaccines
HIV
Acquired Immunodeficiency Syndrome
env Gene Products
Human Immunodeficiency Virus Proteins
HIV Infections
HIV-1
Pharmaceutical Preparations
Proteins

Keywords

  • Adenoviral vector
  • Clinical trial
  • Delivery system
  • Dendritic cell
  • Env
  • HIV
  • Immune response
  • Mucosal immunity
  • Nef
  • Neutralising antibodies
  • Preclinical model
  • Rev
  • SHIV
  • SIV
  • Tat
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Titti, F., Cafaro, A., Ferrantelli, F., Tripiciano, A., Moretti, S., Caputo, A., ... Ensoli, B. (2007). Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opinion on Emerging Drugs, 12(1), 23-48. https://doi.org/10.1517/14728214.12.1.23

Problems and emerging approaches in HIV/AIDS vaccine development. / Titti, Fausto; Cafaro, Aurelio; Ferrantelli, Flavia; Tripiciano, Antonella; Moretti, Sonia; Caputo, Antonella; Gavioli, Riccardo; Ensoli, Fabrizio; Robert-Guroff, Marjorie; Barnett, Susan; Ensoli, Barbara.

In: Expert Opinion on Emerging Drugs, Vol. 12, No. 1, 03.2007, p. 23-48.

Research output: Contribution to journalArticle

Titti, F, Cafaro, A, Ferrantelli, F, Tripiciano, A, Moretti, S, Caputo, A, Gavioli, R, Ensoli, F, Robert-Guroff, M, Barnett, S & Ensoli, B 2007, 'Problems and emerging approaches in HIV/AIDS vaccine development', Expert Opinion on Emerging Drugs, vol. 12, no. 1, pp. 23-48. https://doi.org/10.1517/14728214.12.1.23
Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A et al. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opinion on Emerging Drugs. 2007 Mar;12(1):23-48. https://doi.org/10.1517/14728214.12.1.23
Titti, Fausto ; Cafaro, Aurelio ; Ferrantelli, Flavia ; Tripiciano, Antonella ; Moretti, Sonia ; Caputo, Antonella ; Gavioli, Riccardo ; Ensoli, Fabrizio ; Robert-Guroff, Marjorie ; Barnett, Susan ; Ensoli, Barbara. / Problems and emerging approaches in HIV/AIDS vaccine development. In: Expert Opinion on Emerging Drugs. 2007 ; Vol. 12, No. 1. pp. 23-48.
@article{b5e30cf63e824e70a491bfc9092532dc,
title = "Problems and emerging approaches in HIV/AIDS vaccine development",
abstract = "According to recent estimates, 39.5 million people have been infected with HIV and 2.9 million have already died. The effect of HIV infection on individuals and communities is socially and economically devastating. Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, it has had a negligible impact on the global epidemic. Therefore, the need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of a vaccine against HIV/AIDS has turned out to be extremely challenging, as indicated by > 20 years of unsuccessful attempts. This review discusses the major challenges in the field and key experimental evidence providing a rationale for the use of non-structural HIV proteins, such as Rev, Tat and Nef, either in the native form or expressed by viral vectors such as a replicating adeno-vector. These non-structural proteins alone or in combination with modified structural HIV-1 Env proteins represent a novel strategy for both preventative and therapeutic HIV/AIDS vaccine development.",
keywords = "Adenoviral vector, Clinical trial, Delivery system, Dendritic cell, Env, HIV, Immune response, Mucosal immunity, Nef, Neutralising antibodies, Preclinical model, Rev, SHIV, SIV, Tat, Vaccine",
author = "Fausto Titti and Aurelio Cafaro and Flavia Ferrantelli and Antonella Tripiciano and Sonia Moretti and Antonella Caputo and Riccardo Gavioli and Fabrizio Ensoli and Marjorie Robert-Guroff and Susan Barnett and Barbara Ensoli",
year = "2007",
month = "3",
doi = "10.1517/14728214.12.1.23",
language = "English",
volume = "12",
pages = "23--48",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Problems and emerging approaches in HIV/AIDS vaccine development

AU - Titti, Fausto

AU - Cafaro, Aurelio

AU - Ferrantelli, Flavia

AU - Tripiciano, Antonella

AU - Moretti, Sonia

AU - Caputo, Antonella

AU - Gavioli, Riccardo

AU - Ensoli, Fabrizio

AU - Robert-Guroff, Marjorie

AU - Barnett, Susan

AU - Ensoli, Barbara

PY - 2007/3

Y1 - 2007/3

N2 - According to recent estimates, 39.5 million people have been infected with HIV and 2.9 million have already died. The effect of HIV infection on individuals and communities is socially and economically devastating. Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, it has had a negligible impact on the global epidemic. Therefore, the need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of a vaccine against HIV/AIDS has turned out to be extremely challenging, as indicated by > 20 years of unsuccessful attempts. This review discusses the major challenges in the field and key experimental evidence providing a rationale for the use of non-structural HIV proteins, such as Rev, Tat and Nef, either in the native form or expressed by viral vectors such as a replicating adeno-vector. These non-structural proteins alone or in combination with modified structural HIV-1 Env proteins represent a novel strategy for both preventative and therapeutic HIV/AIDS vaccine development.

AB - According to recent estimates, 39.5 million people have been infected with HIV and 2.9 million have already died. The effect of HIV infection on individuals and communities is socially and economically devastating. Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, it has had a negligible impact on the global epidemic. Therefore, the need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of a vaccine against HIV/AIDS has turned out to be extremely challenging, as indicated by > 20 years of unsuccessful attempts. This review discusses the major challenges in the field and key experimental evidence providing a rationale for the use of non-structural HIV proteins, such as Rev, Tat and Nef, either in the native form or expressed by viral vectors such as a replicating adeno-vector. These non-structural proteins alone or in combination with modified structural HIV-1 Env proteins represent a novel strategy for both preventative and therapeutic HIV/AIDS vaccine development.

KW - Adenoviral vector

KW - Clinical trial

KW - Delivery system

KW - Dendritic cell

KW - Env

KW - HIV

KW - Immune response

KW - Mucosal immunity

KW - Nef

KW - Neutralising antibodies

KW - Preclinical model

KW - Rev

KW - SHIV

KW - SIV

KW - Tat

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33947645357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947645357&partnerID=8YFLogxK

U2 - 10.1517/14728214.12.1.23

DO - 10.1517/14728214.12.1.23

M3 - Article

C2 - 17355212

AN - SCOPUS:33947645357

VL - 12

SP - 23

EP - 48

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -